摘要
Objective:To investigate the expression level of sex-determining region Y-related high mobility group box 4(Sox4)in female lung cancer patients and its clinical significance.Methods:213cases of female lung cancer patients who presented in the third affiliated hospital of Kunming medical university were selected for this study.Patients were performed radical surgery of lung cancer;the tumor and adjacent normal tissues were collected.The expression of Sox4 were determined by real-time PCR and immunohistochemical staining.The correlation between Sox4 expression and clinicopathological characteristics was analyzed.Results:The mRNA level of Sox4 was significantly higher in tumor tissues than that in adjacent normal tissues(P <0.05).The positive expression rate of SOX4 in carcinoma tissues was 54.46%,which was significantly higher than that in adjacent normal tissues(23.47%)(P <0.05).The positive expression rate of Sox4 in stageⅢ was 89.47%,which was significantly higher than that in stageⅠ-Ⅱ(P <0.05).The positive expression rate of SOX4 in lung cancer patients with lymph node metastasis was 90.91%,which was significantly higher than that in patients without lymph node metastasis(P <0.05).The positive expression rates of Sox4 in low,middle and high differentiation tissues were 69.05%,32.88% and 23.21% respectively,suggesting that the expression of Sox4 in female lung cancer tissues decreased with the increase of pathological differentiation grades.Conclusion:In female lung cancer,SOX4expression was significantly higher in tumor tissue than that of adjacent normal tissues and was correlated with clinical stage,lymph node metastasis and pathological differentiation.Sox4 expression detection may help determine the prognosis of women with lung cancer and provide a theoretical basis for molecular targeted therapy of lung cancer in women.
Objective: To investigate the expression level of sex-determining region Y-related high mobility group box 4 (Sox4) in female lung cancer patients and its clinical signifi- cance. Methods:213 cases of female lung cancer patients who presented in the third affiliated hospital of Kunming medical university were selected for this study. Patients were per- formed radical surgery of lung cancer; the tumor and adjacent normal tissues were collected. The expression of Sox4 were determined by real-time PCR and immunohistochemical stai- ning. The correlation between Sox4 expression and clinico pathological characteristics was analyzed. Results:The mRNA level of Sox4 was significantly higher in tumor tissues than that in adjacent normal tissues( P 〈0.05). The positive ex- pression rate of SOX4 in carcinoma tissues was 54. 46%, which was significantly higher than that in adjacent normal tissues(23.47% )( P〈0.05). The positive expression rate of Sox4 in stage Ⅲ was 89.47 % ,which was significantly higher than that in stage Ⅲ ( P d0.05). The positive expression rate of SOX4 in lung cancer patients with lymph node metas- tasis was 90.91 % ,which was significantly higher than that in patients without lymph node metastasis( P 〈0.05). The pos- itive expression rates of Sox4 in low, middle and high differ entiation tissues were 69.05% ,32. 88% and 23.21% respec- tively,suggesting that the expression of Sox4 in female lung cancer tissues decreased with the increase of pathological differentiation grades. Conclusion: In female lung cancer, SOX4 expression was significantly higher in tumor tissue than that of adjacent normal tissues and was correlated with clinical stage,lymph node metastasis and pathological differentiation. Sox4 expression detection may help determine the prognosis of women with lung cancer and provide a theoretical basis for molecular targeted therapy of lung cancer in women.
出处
《广西医科大学学报》
CAS
2016年第6期929-933,共5页
Journal of Guangxi Medical University
基金
supported by grants from the Fund for Less Developed Regions of the National Natural Science Foundation of China(No.81460441)
the Scientific Research Fund for Key Projects of Yunnan Education Department(No.2013Z110)
Special Joint Fund of Yunnan Provincial Science & Technology Bureau-Kunming Medical College(No.2013FB132)